{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Time to hematological improvement - erythroid (HI-E) was assessed as the time from first dose of enasidenib to the first observed hemoglobin response. Participants will be characterized and stratified as non-transfused (NTD), low-transfusion burden (LTB) and high-transfusion burden (HTB), with response defined as follows.\n\n* NTD = greater than or equal to 2 consecutive Hb measurements, greater than or equal to 1.5 g/dL for a period of minimum 8 week in an observation period of 16 to 24 week compared to the lowest mean of 2 Hb measurements\n* LTB = 0 units of RBC transfusions\n* HTB = greater than or equal to 4 unit or greater than or equal to 50% reduction in RBC transfusions","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 100 mg once daily.","id":"OG000","title":"Enasidenib Mesylat 100mg"},{"description":"Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 200 mg once daily.","id":"OG001","title":"Enasidenib Mesylat 200mg"}],"paramType":"MEAN","populationDescription":"No participants achieved Hematological Improvement - Erythroid (HI-E), and therefore no results could be calculated.","reportingStatus":"POSTED","timeFrame":"16 weeks","title":"Time to Hematological Improvement - Erythroid (HI-E)","type":"SECONDARY"}